drugset / Trial / NCT06714383
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
RandomizedParallel-groupSingle-blindPrevention
Summary
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2025-07
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | 240 mg/m2 | Intravenous |
| Background | Lobaplatin | Small molecule | 40 mg/m2 | Intravenous |
| Background | Pirarubicin | Small molecule | 60 mg/m2 | Intravenous |